New York, December 28, 2020 (GLOBE NEWSWIRE) – Reportlinker.com announces release of “Global Systemic Lupus Erythematosus (Sle) Drug Industry” – https://www.reportlinker.com/p05960224/ ? utm_source = GNW
3 Million in the year 2020 is expected to reach a revised volume of US $ 264.5 Million by 2027, growing at a CAGR of 5.4% over the period 2020-2027.
The US accounts for more than 29.5% of global market size in 2020, while China is expected to grow at a CAGR of 5% for the period 2020-2027
The market for the systemic drug Lupus Erythematosus (Sle) in the US is estimated at US $ 54 Million in the year 2020. The country currently accounts for 29.48% share of the global market. China, the second largest economy in the world, is expected to reach an estimated market size of US $ 46.6 Million in the year 2027 slowing a CAGR of 5% through 2027. Other geographic markets include Japan and Canada, all expected to grow at 5.1% and 4.3% respectively over the period 2020-2027. Within Europe, Germany is expected to grow at around 4.4% CAGR while the rest of the European market (as described in the study) reaches US $ 46.6 Million by the year 2027 We will bring years of research experience to this 8th edition of our report. The 105-page report provides accurate insights into how the pandemic affected productivity and the purchasing side for 2020 and 2021. A gradual recovery in the short term is also addressed.
Competitors identified in this market include, among others,
- Amgen, Inc.
- Bristol-Myers Squibb Company
- GlaxoSmithKline PLC
- Immunomedics, Inc.
- Johnson & Johnson
- MedImmune LLC
- Merck Serono GmbH
- Sanofi SA
- Teva Pharmaceutical Industries Limited.
- UCB SA
Read the full report: https://www.reportlinker.com/p05960224/?utm_source=GNW
I. INTRODUCTION, METHODOLOGY & SCOPE OF REPORT
II. SUMMARY
1. MARKET OVERVIEW
Covid-19 impact and global economic downturn
Global competitive market shares
Competitive Lupus Erythematosus Drug Market (Sle)
World position share (in%): 2018E
2. A WORD ON SELECT PLANS
3. MARKET RESULTS & DIFFERENCES
4. GLOBAL MARKET VIEW
Table 1: Global & Future Analysis for Systemic Lupus
Erythematosus (Sle) drugs by geographical area – USA, Canada,
Japan, China, Europe, Asia-Pacific and the rest of the world markets –
Independent Analysis of Annual Sales in US $ Million for Years
2018 through 2027
Table 2: World Historical Review for systemic Lupus Erythematosus
Drugs (Sle) by geographical area – USA, Canada, Japan, China,
Europe, Asia-Pacific and the rest of the world markets – Independent
Analysis of Annual Sales in US $ Million for Years 2012 through
2017
Table 3: 15-Year World View for Systemic Lupus
Erythematosus (Sle) drugs by geographical area – percentage
Breakdown of value sales for USA, Canada, Japan, China, Europe,
Asia-Pacific Markets and Rest of Global Markets for 2012, 2018 &
2027
III. MARKET ANALYSIS
ANALYSIS OF HUMAN MARKETS
UNITED STATES
Table 4: Current & Future Analysis for Systemic Lupus
Erythematosus (Sle) Drugs by Segment – Systemic Lupus
Erythematosus (Sle) Drug – Independent Annual Analysis
Sales in US $ Million for the Year 2018 through 2027
Table 5: US Historical Review for Systemic Lupus Erythematosus
Drugs (Sle) with fragment – Systemic lupus Erythematosus (Sle)
Drug Markets – Independent Analysis of Annual Sales in US $
Million for Years 2012 through 2017
CANADA
Table 6: Current & Future Canadian Study for Systemic Lupus
Erythematosus (Sle) Drugs by Segment – Systemic Lupus
Erythematosus (Sle) Drug – Independent Annual Analysis
Sales in US $ Million for the Year 2018 through 2027
Table 7: Canadian Historical Review for Systemic Lupus
Erythematosus (Sle) Drugs by Segment – Systemic Lupus
Erythematosus Drug Markets (Sle) – Independent Analysis
Annual Sales in US $ Million for the Year 2012 through 2017
JAPAN
Table 8: Japan & current analysis for systemic Lupus
Erythematosus (Sle) Drugs by Segment – Systemic Lupus
Erythematosus (Sle) Drug – Independent Annual Analysis
Sales in US $ Million for the Year 2018 through 2027
Table 9: Japanese Historical Review for systemic Lupus Erythematosus
Drugs (Sle) with fragment – Systemic lupus Erythematosus (Sle)
Drug Markets – Independent Analysis of Annual Sales in US $
Million for Years 2012 through 2017
CHINA
Table 10: China & current analysis for system Lupus
Erythematosus (Sle) Drugs by Segment – Systemic Lupus
Erythematosus (Sle) Drug – Independent Annual Analysis
Sales in US $ Million for the Year 2018 through 2027
Table 11: China Historical Review for Systematic Lupus
Erythematosus (Sle) Drugs by Segment – Systemic Lupus
Erythematosus Drug Markets (Sle) – Independent Analysis
Annual Sales in US $ Million for the Year 2012 through 2017
EUROPE
Table 12: Current & Future European Study for Systemic Lupus
Erythematosus (Sle) drugs by geographical area – France,
Markets Germany, Italy, UK and the rest of Europe – Independent
Analysis of annual sales in US $ Million for Year 2018 through
2027
Table 13: European Historical Review for Systemic Lupus
Erythematosus (Sle) drugs by geographical area – France,
Markets Germany, Italy, UK and the rest of Europe – Independent
Analysis of Annual Sales in US $ Million for Years 2012 through
2017
Table 14: 15-year European Outlook for Systemic Lupus
Erythematosus (Sle) drugs by geographical area – percentage
Breakdown of value sales for France, Germany, Italy, UK and
Rest of European Markets for Years 2012, 2018 & 2027
FRANCE
Table 15: Current & Future Study for Systemic Lupus
Erythematosus (Sle) Drugs by Segment – Systemic Lupus
Erythematosus (Sle) Drug – Independent Annual Analysis
Sales in US $ Million for the Year 2018 through 2027
Table 16: French Historical Review for Systemic Lupus
Erythematosus (Sle) Drugs by Segment – Systemic Lupus
Erythematosus Drug Markets (Sle) – Independent Analysis
Annual Sales in US $ Million for the Year 2012 through 2017
GERMANY
Table 17: Germany Current & Future Analysis for System Lupus
Erythematosus (Sle) Drugs by Segment – Systemic Lupus
Erythematosus (Sle) Drug – Independent Annual Analysis
Sales in US $ Million for the Year 2018 through 2027
Table 18: German Historical Review for Systematic Lupus
Erythematosus (Sle) Drugs by Segment – Systemic Lupus
Erythematosus Drug Markets (Sle) – Independent Analysis
Annual Sales in US $ Million for the Year 2012 through 2017
ITALY
Table 19: Italy Current & future analysis for systemic Lupus
Erythematosus (Sle) Drugs by Segment – Systemic Lupus
Erythematosus (Sle) Drug – Independent Annual Analysis
Sales in US $ Million for the Year 2018 through 2027
Table 20: Italian Historical Review for Systemic Lupus
Erythematosus (Sle) Drugs by Segment – Systemic Lupus
Erythematosus Drug Markets (Sle) – Independent Analysis
Annual Sales in US $ Million for the Year 2012 through 2017
UNITED KINGDOM
Table 21: Routine and forthcoming UK analysis for systemic Lupus
Erythematosus (Sle) Drugs by Segment – Systemic Lupus
Erythematosus (Sle) Drug – Independent Annual Analysis
Sales in US $ Million for the Year 2018 through 2027
Table 22: UK Historical Review for systemic Lupus Erythematosus
Drugs (Sle) with fragment – Systemic lupus Erythematosus (Sle)
Drug Markets – Independent Analysis of Annual Sales in US $
Million for Years 2012 through 2017
EUROPEAN CHANGE
Table 23: Rest of Europe Current & future study for systematic
Drugs Lupus Erythematosus (Sle) by Segment – Systemic Lupus
Erythematosus (Sle) Drug – Independent Annual Analysis
Sales in US $ Million for the Year 2018 through 2027
Table 24: Historical Review of the Rest of Europe for Systematic Lupus
Erythematosus (Sle) Drugs by Segment – Systemic Lupus
Erythematosus Drug Markets (Sle) – Independent Analysis
Annual Sales in US $ Million for the Year 2012 through 2017
ASIA-PACIFIC
Table 25: Current & future analysis for systematic
Drugs Lupus Erythematosus (Sle) by Segment – Systemic Lupus
Erythematosus (Sle) Drug – Independent Annual Analysis
Sales in US $ Million for the Year 2018 through 2027
Table 26: Asia-Pacific Historical Review for Systematic Lupus
Erythematosus (Sle) Drugs by Segment – Systemic Lupus
Erythematosus Drug Markets (Sle) – Independent Analysis
Annual Sales in US $ Million for the Year 2012 through 2017
REVIEW OF THE WORLD
Table 27: Rest of current & future analysis for systematic
Drugs Lupus Erythematosus (Sle) by Segment – Systemic Lupus
Erythematosus (Sle) Drug – Independent Annual Analysis
Sales in US $ Million for the Year 2018 through 2027
Table 28: Rest of World Historical Review for System Lupus
Erythematosus (Sle) Drugs by Segment – Systemic Lupus
Erythematosus Drug Markets (Sle) – Independent Analysis
Annual Sales in US $ Million for the Year 2012 through 2017
IV. TABLE
Total Companies Profile: 41
Read the full report: https://www.reportlinker.com/p05960224/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest business data so you can get all the market research you need – instantly, in one place.
__________________________
Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001